Methods. Patients presenting with visual complaints and active or healed HZO at the ophthalmology outpatient department of three hospitals in rural South Africa were included in this study.
INTRODUCTION
Herpes zoster ophthalmicus (HZO) is the clinical manifestation of reactivation of latent varicellazoster virus (VZV) infection located within the ophthalmic branch of the trigeminal nerve. [1] [2] [3] [4] Due to impaired cell-mediated immunity, human immunodeficiency virus (HIV)-infected individuals are at increased risk of developing HZO (relative incident risk of 6.6) compared to HIV-uninfected individuals. [5] [6] [7] [8] If cutaneous HZO is left untreated, ocular involvement occurs in more than half of patients and leads to chronic debilitating pain, visual impairment and eventually (unilateral) blindness. [1] [2] [3] 9 These ocular complications are more common among HIV-infected individuals and have a more severe clinical presentation and higher recurrence rate, especially in individuals with low CD4 count. 1, 3, 6, 8 The spectrum of ocular complications of HZO is diverse. Corneal inflammation and opacification (49-89%) and anterior uveitis (43-92%) are the most common complications, but ocular cranial-nerve palsies, neuralgia, eyelid deformities, (blepharo-)conjunctivitis, (epi-)scleritis and optic neuritis may also occur. [1] [2] [3] [4] 7, [9] [10] [11] [12] [13] In the acute phase of HZO 'early' corneal complications are may develop such as punctate epithelial keratitis and dendritic keratitis; these are associated with minimal risk of visual impairment. However, if left untreated, progression to chronic, late-stage corneal complications with serious visual impairment due to corneal opacification and ulceration may develop. 1, 3 Additionally, in cases where uveitis occurs, mild HZO-associated acute anterior uveitis may progress to sight-threatening stages due to chronic inflammation leading to corneal oedema, iris atrophy, posterior synaechiae and cataract formation. 3, 7 Thus, early recognition of ocular involvement in HZO patients and subsequent initiation of targeted oral and topical treatment is essential to prevent ocular morbidity.
South Africa is highly affected by the HIV epidemic and the clinical presentation of dermal HZO is relatively common. 14 Data on ocular manifestations of HZO in HIV-infected sub-Saharan Africans are scarce. 9, 14, 15 The aim of this study was to describe the spectrum of ocular complications 4 of HZO and, in particular, to distinguish between early and late stage ocular complications as these impact on visual prognosis.
METHODS

Study setting and population
This study was conducted at the ophthalmology outpatient department of three hospitals in rural South Africa (Mopani District) and is a sub-analysis of data collected in Anova's Mopani Eye Project.
Briefly, this project aimed to improve eye care through a combination of clinical research and health systems strengthening activities. For this analyses, cases were selected from three ongoing clinical studies initiated with the following objectives: to determine the (1) aetiology of uveitis, (2) aetiology of infectious keratitis and (3) impact of HIV infection and antiretroviral therapy (ART) on the eye (Schaftenaar E, Mopani Eye Project 2015, unpublished data). Adults (≥18 years old) with a clinical diagnosis of uveitis or infectious keratitis were included in the first two studies and adults with documented HIV infection, regardless presence of eye complaints, were included in the third study.
Individuals presenting in either of these studies with active or healed HZO were included in the current analysis.
HZO diagnosis was defined as presence of a primary vesiculomacular and dysesthetic skin rash or typical scar (with matching clinical history of HZO) within the ophthalmic dermatome. 7, 16 Demographic and clinical data were collected at enrolment in all three studies. Each participant had a full ophthalmic examination, including measurement of visual acuity, slit-lamp examination and dilated indirect ophthalmoscopy. Visual acuity testing was performed using an "illiterate E" Snellen chart at a distance of 6 meter and visual acuity was defined as the lowest line value where at least half the letters were correctly identified by the participant without correction of the affected eye. If visual acuity was <6/60, the distance between the Snellen chart and patient was reduced to 3 or 1 5 meter. If visual acuity was <1/60, "hand movements", "light perception" or "no light perception" was recorded. Visual impairment was defined according to the International Classification of Diseases (ICD-10, version 2010) on basis of the individual's visual acuity. 17 The studies were approved by the Human Research Ethics Committee (University of the Witwatersrand;
Johannesburg, South Africa) and written informed consent (including ocular photography) was obtained from all participants.
Classification of early and late ocular complications
Ocular complications were classified as "early" or "late" based on stage of disease progression and (potential) restoration of normal vision. The following manifestations were classified as early stage:
eyelid oedema, (blepharo-)conjunctivitis, (epi-)scleritis, punctate epithelial keratitis, pseudodendritic or dendritic keratitis, nummular keratitis and/or anterior uveitis. 7 Late stage ocular complications were in case of eyelid scarring, trichiasis, entropion, ptosis, deep stromal keratitis, disciform keratitis, corneal ulceration, neurotrophic keratopathy, necrotising retinitis, retinal detachment and optic neuritis. Although necrotising retinitis and optic neuritis may also occur in the early phase, we decided to include both as late stage ocular complications due to their devastating effect on visual acuity.
7
Data analysis
Data were double-entered and validated using EPI-INFO version 3.5. presented with healed (no active skin lesions) and 9 patients (19%) with active HZO. HZO was unilateral except for two cases. Median days between reported onset of eye complaints and first presentation to the ophthalmology outpatient department was 35 days (range 1-2500 days).
Poor vision (94%) was the most common ocular symptom, followed by a painful eye (79%) and photophobia (63%). A diverse spectrum of ocular HZO complications was observed (Figure 1) , with corneal inflammation and opacification (77%) as the most common ocular complication followed by anterior uveitis (65%) ( Table 1 At enrolment we observed a significant rate of visual disability and blindness (81%). Although we did not report on visual acuity after HZO-specific treatment, we expect the final rate of visual disability and blindness to be high since the majority presented with late stage manifestations associated with often irreversible visual impairment and blindness. 1, 3, 7 The observed high rate of visual disability was similar to two previous studies from Africa twenty years ago. 9, 15 There was a considerable delay (median time of 35 days) between onset of symptoms and first presentation to the ophthalmology outpatient department; such delay was associated with late stage ocular complications. The association between delay to the ophthalmology outpatient department and late stage complications might be due to delayed initiation of antiviral treatment as early initiation thereof (≤72 hours after onset of rash) reduces the risk of progression to late stage ocular complications. 3, 18 The delay observed in our study is long and much higher than reported by a similar study conducted at the ophthalmology outpatient department of the Groote Schuur Hospital (Cape Town, South Africa) in which a median delay of 5 days was reported. 14 Both patient-and healthcare system-associated factors may have contributed to this discrepancy. healthcare facilities before presenting to our ophthalmology outpatient departments.
Healed HZO was associated with late stage ocular complications. However, seemingly contradictory, early ocular complications were observed in 11 (28%) patients, all of whom were HIVinfected, presenting with healed HZO. Although no demographic and clinical characteristics, including CD4 count, were associated with these 11 patients, the early stage ocular complications observed in these healed HZO patients may be due to higher frequency of local (e.g. corneal)
recrudescence of VZV due to HIV-induced immune senescence. [5] [6] [7] [8] Also, late stage ocular complications were observed in three (33%) HIV-infected patients with active HZO. Since HIV infection is associated with more severe ocular disease in HZO, these three patients may have developed late stage ocular complications early after onset of disease. 1, 3, 6, 8 Most HZO patients included in our study were HIV infected and were significant younger than HIV-uninfected individuals. This is in agreement with previous HZO studies from sub-Saharan Africa. 9, 12, 14 Among the HIV-infected individuals, four (10%) HZO patients were tested reactive for HIV for the first time as they were offered provided-initiated HIV testing based on their clinical presentation. This highlights the importance of providing HIV testing to individuals presenting with HZO as advocated in previous studies. 1, 8, 10, 21, 22 A potential limitation is the study design whereby potential HZO patients were selected from three different clinical studies. However, selection bias is unlikely, because any individual with HZO presenting with ocular complaints was eligible for participation in one of our studies. Due to selection of individuals with ocular HZO complications, no inferences could be made about the 9 prevalence of ocular HZO complications in the general population of the Mopani District. Finally, because diagnosis was solely based on the patient's history and clinical characteristics, not all observed ocular HZO complications may be caused directly by VZV as involvement of other viruses or even an ocular bacterial superinfection are optional. However, the latter is unlikely because the sensitivity and specificity of the clinical characteristics in combination with active or healed HZO lesions are very disease-specific. 16, 23 In this study, we demonstrated that HZO patients presenting to the ophthalmology outpatient department of three hospitals in rural South Africa have relatively late stage ocular complications and that this is associated with serious visual impairment and blindness. This emphasizes the importance of early recognition of ocular involvement in HZO and subsequent initiation of appropriate antiviral treatment at primary healthcare level with prompt referral to hospitals with ophthalmology departments to reduce these sight-threatening ocular complications.
As such, appropriate antiviral treatment should be available at primary healthcare level, even in rural settings. Furthermore, to prevent HZO-associated ocular morbidity, development of clinical guidelines and training programmes for healthcare workers as well as health system strengthening and community awareness are of paramount importance. These efforts will improve prevention and clinical management of ocular HZO complications and reduce the burden of avoidable visual impairment and blindness in South Africa. We thank all patients who participated in this study. Our further gratitude goes to the staff of Anova Health Institute (Johannesburg and Tzaneen, South Africa) and the staff of the ophthalmology outpatient department of the three hospitals in the Mopani District that participated in this study for their invaluable contribution, efforts and support. We also thank Vincent Schaftenaar for refining the figure included in this manuscript. 
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